IP Library Granted Patent US 8,394,364
Granted Patent B2
US 8,394,364 · App. 12/845,544 · Granted Mar 12, 2013

Methods of using ophthalmic compositions comprising povidone-iodine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,364
App. No.
12/845,544
Granted
Mar 12, 2013
Kind
B2
Abstract

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.

Claims (19)

1. A method for treating at least one member selected from the group consisting of:

a. a microorganism infection of at least one tissue of the eye,

b. conjunctivitis, and

c. a microorganism infection of at least one tissue of the eye following corneal abrasion or ocular surgery,

comprising the step of administering one or more doses of an ophthalmic composition to said eye, wherein the composition is suitable for topical administration to an eye, comprising a mixture of povidone-iodine in a concentration between 0.01% and 4% by weight and a steroid, wherein the steroid is dexamethasone, and wherein, after a period of one month after mixing the steroid and povidone-iodine to form the composition, the steroid concentration is at least 90% of the steroid starting concentration.

2. The method of claim 1 , wherein said microorganism is a bacteria, virus, fungi, or amoebae.

3. The method of claim 2 wherein said bacteria is mycobacteria.

4. The method of claim 1 wherein the sum of said povidone-iodine and said steroid is between 0.001 mg to 5 mg per dose.

5. The method of claim 1 wherein each dose is between 10 microliters to 200 microliters.

6. The method of claim 1 wherein each dose is between 50 microliters to 80 microliters.

7. The method of claim 1 wherein said administering comprises administering said solution to said eye one to four times a day.

8. The method of claim 1 wherein said administering comprises administering said solution to said eye one to twenty-four times a day.

9. The method of claim 1 further comprising the step of storing the composition for at least one month, at least three months, at least six months, or at least 1 year before said administration step.

10. The method of claim 9 wherein said storing is in a lighted environment.

11. A method for prophylaxis of one of the members selected from the group consisting of:

a. a microorganism infection of at least one tissue of the eye,

b. conjunctivitis, and

c. a microorganism infection of at least one tissue of the eye following corneal abrasion or ocular surgery,

comprising the step of administering one or more doses of a composition to said eye, wherein the composition is suitable for topical administration to an eye, comprising a mixture of povidone-iodine in a concentration between 0.01% and 4% by weight and a steroid, wherein the steroid is dexamethasone, and wherein, after a period of one month after mixing the steroid and povidone-iodine to form the composition, the steroid concentration is at least 90% of the steroid starting concentration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2017
From: CLS PHARMACEUTICALS, INC.
To: CLARUS CLS HOLDINGS, LLC
Reel/Frame 043437/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2016
From: SAMSON, C. MICHAEL; LIANG, BO; CAPRIOTTI, JOSEPH A.
To: CLS PHARMACEUTICALS, INC.
Reel/Frame 039764/0315 →